NEW DELHI: One more vaccine is all set to counter Covid-19. The Covovax, manufactured by Serum Institute of India (SII), has received emergency use authorization from the Drugs Controller General of India (DCGI). It has been authorized to be administered to adolescents aged between 12 to 18 in India. Covovax has been developed by the SII in association with the United States’ Novavox. It is the first protein-based vaccine authorized for use in this age group in India. Last year, the DCGI had approved the administration of Covaxin to those aged above 18 years.